

Europe Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Molecular, Conventional), By Infection Type (UTI, Pneumonia), By Product (Consumables, Instruments), By Type, By Country, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/ED5FAD4AD2FDEN.html>

Date: February 2025

Pages: 100

Price: US\$ 5,950.00 (Single User License)

ID: ED5FAD4AD2FDEN

Abstracts

This report can be delivered to the clients within 3 Business Days

Europe Hospital Acquired Infections Diagnostics Market Growth & Trends

The Europe hospital acquired infections diagnostics market size is anticipated to reach USD 1.61 billion by 2030, growing at a CAGR of 1.2% during the forecast period, according to a new report by Grand View Research, Inc. In recent years, the prevalence of infections, particularly sepsis and surgical site infections, has driven a surge in demand for effective diagnostic solutions. In Europe, approximately 3.4 million sepsis cases occurred annually, leading to nearly 700,000 deaths each year, highlighting the urgent need for advanced diagnostic tools. The rising incidence of bloodstream infections (BSIs) compelled healthcare providers to implement robust diagnostic measures, presenting substantial market opportunities for companies specializing in hospital-acquired infection (HAI) diagnostics.

Technological advancements significantly contributed to market growth, with innovations in molecular diagnostics and rapid testing methods enhancing the accuracy and speed of HAI detection. These developments allowed for more timely identification, ultimately improving patient outcomes.

In addition, increasing healthcare expenditure across European countries facilitated the adoption of HAI diagnostics. Investments in healthcare infrastructure and proactive government initiatives aimed at infection control fostered a supportive environment for

market expansion. Heightened patient awareness regarding HAIs further amplified the demand for effective diagnostic solutions, as informed patients and healthcare providers alike sought timely diagnostics, propelling market growth for innovative diagnostic products.

Europe Hospital Acquired Infections Diagnostics Market Report Highlights

Based on test type, the conventional tests dominated the market in 2024. Molecular tests, especially PCR-based methods, are projected to achieve the fastest CAGR of 1.5% during the forecast period, becoming essential for diagnosing hospital-acquired infections in Europe.

Based on infection type, the UTI segment led the Europe hospital acquired infections diagnostics industry in 2024, accounting for a revenue share of 21.6% in 2024.

In 2024, the consumables product segment captured the highest market share, driven by the need for accurate diagnosis, regulatory compliance, and high testing volumes in European hospitals.

Based on type, the urinalysis segment is expected to grow lucratively due to rising UTI rates in hospitals, particularly in urology units, driven by high catheterization and demand for effective diagnostics.

Key players operating in the market include BIOMERIEUX; Abbott; F. Hoffmann-La Roche Ltd; Siemens Healthineers AG; BD; HC Bioscience; QIAGEN; ThermFisher Scientific Inc.; Meridian Bioscience, Inc.; Hologic, Inc.

In January 2025, BioMerieux announced its intent to pursue acquisitions with EUR 3bn- EUR 4bn available, enhancing its core segments within the diagnostics market.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Test Type
 - 1.2.2. Infection Type
 - 1.2.3. Product
 - 1.2.4. Type
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. EUROPE HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis

- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
 - 3.3.1.1. Supplier Power
 - 3.3.1.2. Buyer Power
 - 3.3.1.3. Substitution Threat
 - 3.3.1.4. Threat of New Entrants
 - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

CHAPTER 4. EUROPE HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET: TEST TYPE BUSINESS ANALYSIS

- 4.1. Test Type Market Share, 2024 & 2030
- 4.2. Test Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2018 to 2030 (USD Million)
- 4.4. Molecular
 - 4.4.1. Molecular Market, 2018 - 2030 (USD Million)
- 4.5. Conventional
 - 4.5.1. Conventional Market, 2018 - 2030 (USD Million)

CHAPTER 5. EUROPE HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET: INFECTION TYPE BUSINESS ANALYSIS

- 5.1. Infection Type Market Share, 2024 & 2030
- 5.2. Infection Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Infection Type, 2018 to 2030 (USD Million)
- 5.4. UTI
 - 5.4.1. UTI Market, 2018 - 2030 (USD Million)
- 5.5. Pneumonia
 - 5.5.1. Pneumonia Market, 2018 - 2030 (USD Million)
- 5.6. Surgical Site Infection
 - 5.6.1. Surgical Site Infection Market, 2018 - 2030 (USD Million)
- 5.7. Blood Stream Infections
 - 5.7.1. Blood Stream Infections Market, 2018 - 2030 (USD Million)
- 5.8. Others
 - 5.8.1. Others Market, 2018 - 2030 (USD Million)

CHAPTER 6. EUROPE HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS

MARKET: PRODUCT BUSINESS ANALYSIS

- 6.1. Product Market Share, 2024 & 2030
- 6.2. Product Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 6.4. Consumables
 - 6.4.1. Consumables Market, 2018 - 2030 (USD Million)
- 6.5. Instruments
 - 6.5.1. Instruments Market, 2018 - 2030 (USD Million)

CHAPTER 7. EUROPE HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET: TYPE BUSINESS ANALYSIS

- 7.1. Type Market Share, 2024 & 2030
- 7.2. Type Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 7.4. Blood Tests
 - 7.4.1. Blood Tests Market, 2018 - 2030 (USD Million)
- 7.5. Urinalysis
 - 7.5.1. Urinalysis Market, 2018 - 2030 (USD Million)

CHAPTER 8. EUROPE HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 8.1. Country Market Share Analysis, 2024 & 2030
- 8.2. Country Market Dashboard
- 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.4. UK
 - 8.4.1. Key Country Dynamics
 - 8.4.2. Regulatory Framework
 - 8.4.3. Competitive Insights
 - 8.4.4. UK Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5. Germany
 - 8.5.1. Key Country Dynamics
 - 8.5.2. Regulatory Framework
 - 8.5.3. Competitive Insights
 - 8.5.4. Germany Hospital Acquired Infections Diagnostics Market Estimates And

Forecasts, 2018 - 2030 (USD Million)

8.6. France

8.6.1. Key Country Dynamics

8.6.2. Regulatory Framework

8.6.3. Competitive Insights

8.6.4. France Hospital Acquired Infections Diagnostics Market Estimates And

Forecasts, 2018 - 2030 (USD Million)

8.7. Italy

8.7.1. Key Country Dynamics

8.7.2. Regulatory Framework

8.7.3. Competitive Insights

8.7.4. Italy Hospital Acquired Infections Diagnostics Market Estimates And Forecasts,

2018 - 2030 (USD Million)

8.8. Spain

8.8.1. Key Country Dynamics

8.8.2. Regulatory Framework

8.8.3. Competitive Insights

8.8.4. Spain Hospital Acquired Infections Diagnostics Market Estimates And

Forecasts, 2018 - 2030 (USD Million)

8.9. Norway

8.9.1. Key Country Dynamics

8.9.2. Regulatory Framework

8.9.3. Competitive Insights

8.9.4. Norway Hospital Acquired Infections Diagnostics Market Estimates And

Forecasts, 2018 - 2030 (USD Million)

8.10. Denmark

8.10.1. Key Country Dynamics

8.10.2. Regulatory Framework

8.10.3. Competitive Insights

8.10.4. Denmark Hospital Acquired Infections Diagnostics Market Estimates And

Forecasts, 2018 - 2030 (USD Million)

8.11. Sweden

8.11.1. Key Country Dynamics

8.11.2. Regulatory Framework

8.11.3. Competitive Insights

8.11.4. Sweden Hospital Acquired Infections Diagnostics Market Estimates And

Forecasts, 2018 - 2030 (USD Million)

8.12. Russia

8.12.1. Key Country Dynamics

- 8.12.2. Regulatory Framework
- 8.12.3. Competitive Insights
- 8.12.4. Russia Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.13. Netherlands
 - 8.13.1. Key Country Dynamics
 - 8.13.2. Regulatory Framework
 - 8.13.3. Competitive Insights
 - 8.13.4. Netherlands Hospital Acquired Infections Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

CHAPTER 9. COMPETITIVE LANDSCAPE

- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
 - 9.5.1. BIOM?RIEUX
 - 9.5.1.1. Overview
 - 9.5.1.2. Financial Performance
 - 9.5.1.3. Product Benchmarking
 - 9.5.1.4. Strategic Initiatives
 - 9.5.2. Abbott
 - 9.5.2.1. Overview
 - 9.5.2.2. Financial Performance
 - 9.5.2.3. Product Benchmarking
 - 9.5.2.4. Strategic Initiatives
 - 9.5.3. F. Hoffmann-La Roche Ltd
 - 9.5.3.1. Overview
 - 9.5.3.2. Financial Performance
 - 9.5.3.3. Product Benchmarking
 - 9.5.3.4. Strategic Initiatives
 - 9.5.4. Siemens Healthineers AG
 - 9.5.4.1. Overview
 - 9.5.4.2. Financial Performance
 - 9.5.4.3. Product Benchmarking
 - 9.5.4.4. Strategic Initiatives
 - 9.5.5. BD

- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. HC Bioscience
 - 9.5.6.1. Overview
 - 9.5.6.2. Financial Performance
 - 9.5.6.3. Product Benchmarking
 - 9.5.6.4. Strategic Initiatives
- 9.5.7. QIAGEN
 - 9.5.7.1. Overview
 - 9.5.7.2. Financial Performance
 - 9.5.7.3. Product Benchmarking
 - 9.5.7.4. Strategic Initiatives
- 9.5.8. Thermo Fisher Scientific Inc.
 - 9.5.8.1. Overview
 - 9.5.8.2. Financial Performance
 - 9.5.8.3. Product Benchmarking
 - 9.5.8.4. Strategic Initiatives
- 9.5.9. Meridian Bioscience, Inc.
 - 9.5.9.1. Overview
 - 9.5.9.2. Financial Performance
 - 9.5.9.3. Product Benchmarking
 - 9.5.9.4. Strategic Initiatives
- 9.5.10. Hologic, Inc.
 - 9.5.10.1. Overview
 - 9.5.10.2. Financial Performance
 - 9.5.10.3. Product Benchmarking
 - 9.5.10.4. Strategic Initiatives

I would like to order

Product name: Europe Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Molecular, Conventional), By Infection Type (UTI, Pneumonia), By Product (Consumables, Instruments), By Type, By Country, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/ED5FAD4AD2FDEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ED5FAD4AD2FDEN.html>